Catalyst Pharmaceuticals (Nasdaq:CPRX) - Hisse Senedi Fiyatı, Haberler ve Analizler

CPRX Stoklara Genel Bakış

CPRX temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	5/6
Geçmiş Performans	2/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Trading at 69.5% below our estimate of its fair value

Earnings are forecast to grow 20.89% per year

Analysts in good agreement that stock price will rise by 38.4%

Risk Analizi

Shareholders have been diluted in the past year

Significant insider selling over the past 3 months

Profit margins (15.7%) are lower than last year (38.1%)

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

Successful Product Expansions And Global Partnerships Fuel Revenue Surge And Profit Growth

Key Takeaways Diversification and expansion strategies, including new product launches and international partnerships, contribute to financial stability and potential global revenue growth. Increased daily dosage of key products and strategic capital management bolster revenue per patient and overall profitability, reflecting a foundation for sustained growth.

View narrative

US$30.29

27.7% undervalued

16.18%

Revenue growth p.a.

4 days ago

Catalyst Pharmaceuticals, Inc. Rakipler

MannKind

NasdaqGM:MNKD

US$2.0b

ADMA Biologics

NasdaqGM:ADMA

US$4.5b

ACADIA Pharmaceuticals

NasdaqGS:ACAD

US$2.5b

Agios Pharmaceuticals

NasdaqGS:AGIO

US$2.6b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Catalyst Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$21.89
52 Haftanın En Yüksek Seviyesi	US$22.27
52 Haftanın En Düşük Seviyesi	US$12.27
Beta	0.76
11 Aylık Değişim	9.45%
3 Aylık Değişim	35.21%
1 Yıllık Değişim	68.51%
33 Yıllık Değişim	248.57%
5 Yıllık Değişim	336.06%
Halka arzdan bu yana değişim	258.85%

Son Haberler & Güncellemeler

Recent updates

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jul 24

Catalyst Pharmaceuticals: New Products In Proving Phase

Jul 06

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Apr 06

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jan 29

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Jan 17

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Sep 06

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

May 27

Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Feb 13

Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?

Nov 11

Catalyst Pharmaceuticals gains 9% on SmallCap 600 addition

Sep 12

Catalyst Pharma ends momentum as Roth downgrades

Aug 24

Hissedar Getirileri

	CPRX	US Biotechs	US Pazar
7D	0.1%	-0.7%	-1.6%
1Y	68.5%	19.8%	30.8%

Getiri vs. Endüstri: CPRX exceeded the US Biotechs industry which returned 19.8% over the past year.

Getiri vs Piyasa: CPRX exceeded the US Market which returned 30.8% over the past year.

Fiyat Oynaklığı

Is CPRX's price volatile compared to industry and market?
CPRX volatility
CPRX Average Weekly Movement	5.6%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: CPRX has not had significant price volatility in the past 3 months compared to the US market.

Zaman İçindeki Volatilite: CPRX's weekly volatility (6%) has been stable over the past year.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2002	167	Rich Daly	www.catalystpharma.com

Ticari aşamada bir biyofarmasötik şirketi olan Catalyst Pharmaceuticals Inc., Amerika Birleşik Devletleri'nde nadir görülen zayıflatıcı, kronik nöromüsküler ve nörolojik hastalıkları olan kişiler için tedaviler geliştirmeye ve ticarileştirmeye odaklanmaktadır. Lambert-eaton miyastenik sendromlu (LEMS) hastaların tedavisi için bir amifampridin fosfat tablet olan Firdapse'i ve pediatrik LEMS hastalarının tedavisi için Ruzurgi'yi sunmaktadır. Şirket, MuSK antikoru pozitif myastenia gravis ve spinal musküler atrofi tipinin tedavisi için Firdapse'i geliştirmektedir.

Catalyst Pharmaceuticals, Inc. Temel Bilgiler Özeti

Catalyst Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
CPRX temel i̇stati̇sti̇kler
Piyasa değeri	US$2.60b
Kazançlar(TTM)	US$68.15m
Gelir(TTM)	US$434.48m

38.1x

F/K Oranı

6.0x

P/S Oranı

CPRX aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
CPRX gelir tablosu (TTM)
Gelir	US$434.48m
Gelir Maliyeti	US$151.27m
Brüt Kâr	US$283.20m
Diğer Giderler	US$215.05m
Kazançlar	US$68.15m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

Nov 06, 2024

Hisse başına kazanç (EPS)	0.57
Brüt Marj	65.18%
Net Kâr Marjı	15.69%
Borç/Özkaynak Oranı	0%

CPRX uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

CPRX Stoklara Genel Bakış

Ödüller

Risk Analizi

Successful Product Expansions And Global Partnerships Fuel Revenue Surge And Profit Growth

Catalyst Pharmaceuticals, Inc. Rakipler

NasdaqGM:MNKD

US$2.0b

NasdaqGM:ADMA

US$4.5b

NasdaqGS:ACAD

US$2.5b

NasdaqGS:AGIO

US$2.6b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Catalyst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Independent Director notifies of intention to sell stock

Executive VP recently sold US$3.1m worth of stock

Executive VP notifies of intention to sell stock

Investor sentiment improves as stock rises 19%

Recent updates

Catalyst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Independent Director notifies of intention to sell stock

Executive VP recently sold US$3.1m worth of stock

Executive VP notifies of intention to sell stock

Investor sentiment improves as stock rises 19%

Consensus EPS estimates increase by 16%

Chief Medical & Regulatory Officer notifies of intention to sell stock

Price target increased by 8.4% to US$29.57

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Revises Revenue Guidance for the Full-Year 2024

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Catalyst Pharmaceuticals: New Products In Proving Phase

Chief Medical & Regulatory Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Full-Year 2024

First quarter 2024 earnings: EPS misses analyst expectations

Catalyst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Catalyst Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Independent Director notifies of intention to sell stock

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Insider recently sold US$411k worth of stock

Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (Dmd)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Catalyst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Catalyst Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Co-Founder exercised options to buy US$4.3m worth of stock.

Investor sentiment improves as stock rises 15%

Price target increased by 13% to US$26.20

Catalyst Pharmaceuticals, Inc. Announces Firapse New Drug Application Submitted in Japan by Partner DyDo Pharma

COO & Chief Scientific Officer recently sold US$570k worth of stock

COO & Chief Scientific Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Appoints Michael W. Kalb as Its Chief Financial Officer, Effective on January 1, 2024

Catalyst Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Catalyst Pharmaceuticals, Inc. Receives Two New U.S. Patent Allowances for FIRDAPSE

Catalyst Pharmaceuticals, Inc. Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

Catalyst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Catalyst Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Announces FDA Acceptance of the Supplemental New Drug Application for Firapse

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Catalyst Pharmaceuticals, Inc. Announces the Resignation of Philip H. Coelho as Independent Member of the Board

Catalyst Pharmaceuticals, Inc. Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to Be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer

Second quarter 2023 earnings released: EPS: US$0.35 (vs US$0.21 in 2Q 2022)

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2023

Catalyst Pharmaceuticals, Inc. Announces Resignation of Patrick J. Mcenany as Chief Executive Officer

Catalyst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Catalyst Pharmaceuticals, Inc., Annual General Meeting, Aug 22, 2023

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

Consensus EPS estimates fall by 23%

Investor sentiment deteriorates as stock falls 28%

COO & Chief Scientific Officer exercised options to buy US$1.3m worth of stock.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind